Can molecular stratification improve the treatment of inflammatory bowel disease?. (October 2019)

• Record Type: Journal Article
• Authors: Wang, Claire; Baer, Hannah M.; Gaya, Daniel R.; Nibbs, Robert J.B.; Milling, Simon
• Is Part Of: Pharmacological research. Volume 148(2019)
• Publication Date: 2019-10
• Subjects: ASCA anti-Saccharomyces cerevisae antibody -- AMP anti-microbial peptide -- ATG16L1 autophagy-related 16-like 1 gene -- CD Crohn's disease -- CRP C-reactive protein -- EIM extraintestinal manifestation -- GI gastrointestinal -- GWAS genome-wide association studies -- IBD inflammatory bowel disease -- IFNγ interferon-γ -- IFX infliximab -- IL interleukin -- IL-10R interleukin-10 receptor -- ILC innate lymphoid cell -- mTNF membrane-bound tumour necrosis factor- -- MVKD mevalonate kinase deficiency -- NK natural killer -- NOD2 Nucleotide-binding oligomerisation domain 2 -- OSM oncostatin M -- OSMR oncostatin M receptor -- pANCA perinuclear anti-neutrophil cytoplasmic antibody -- RS risk score -- SNP single nucleotide polymorphism -- TGF transforming growth factor- -- Th T helper -- TNF tumour necrosis factor- -- Treg T regulatory cell -- UC ulcerative colitis; Inflammatory bowel disease -- Crohn's disease -- Ulcerative Colitis -- Molecular stratification -- Anti-TNF -- Treatment response -- Precision medicine -- Disease stratification -- Biologics -- Faecal calprotectin -- Serological markers -- Genomics -- Transcriptomics -- Microbiomics -- Proteomics -- CD -- UC; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2019.104442
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Inflammatory bowel disease (IBD) is a debilitating chronic inflammatory disease of the gastrointestinal (GI) tract. It affects more than 3.5 million people in the western world and places a huge financial burden on healthcare systems. IBD is highly heterogeneous; disease severity and outcomes in IBD are highly variable, and patients may experience episodes of relapse and remission. However, treatment often follows a step-up model whereby the patients start with anti-inflammatory agents (corticosteroids or immunosuppressants) and step-up to monoclonal anti-tumour necrosis factor-α (TNFα) antibodies and then other biologics if the initial drugs cannot control disease. Unfortunately, many patients do not respond to the costly biologics, and thus often still require gut-resective surgery, which decreases quality of life. In order to decrease rates of surgery and ineffective treatments, it is important to identify markers that accurately predict disease progression and treatment responses, to inform decisions about the best choice of therapeutics. Here we examine molecular approaches to patient stratification that aim to increase the effectiveness of treatments and potentially reduce healthcare costs. In the future, it may become possible to stratify patients based on their suitability for specific molecular-targeted therapeutic agents, and eventually use molecular stratification for personalised medicine in IBD.